Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immunovant, Inc.

IMVT ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$28.39

▼ -5.05%

Market Cap $5.86B · Vol 507.01K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.86B

Mid Cap

Div Yield

N/A

EPS Growth

-6.36%

YoY

RSI (14)

58.81

Momentum

Beta

0.94

vs Market

52W High

$45.35

37.40% below

52W Low

$21.43

32.48% above

Volume

507.01K

Avg 514.10K

P/B

5.94

Price-to-book

ROE

-64.82%

Return on equity

Free Float

43.33%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Immunovant, Inc. (IMVT) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMVT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.22%

-14.62%

-27.72%

+1.98%

YTD

+11.68%

+20.30%

-15.86%

+230.89%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-505,606,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-64.82%
ROA · ROIC	-58.32% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.94
P/FCF	N/A
EPS Growth	-6.36%
Outstanding Shares	206.55M

Technical Indicators

50-Day SMA	$33.37
200-Day SMA	$32.10
RSI (14)	58.81
Beta	0.94
52-Week High	$45.35
52-Week Low	$21.43

Volume Today	507.01K
Avg Daily Volume (30D)	514.10K
Relative Volume	0.99x
Volatility (10D)	40.55
Volatility (30D)	38.04
Free Float	43.33%

Analyst Consensus

BUY

Current Price $28.39

Mean Target $48.80

52W Low$21.43 52W High$45.35

Current

Target

$21.43 $45.35

Current Analyst target

+71.89% upside potential · 15 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00P5MC0R7

ISINUS45258J1025

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.63% ONC BeOne Medicines AG +2.51% 068270.KS Celltrion, Inc. +7.50% MEDP Medpace Holdings, Inc. -3.32% ICLR ICON PLC -0.72%

Company Profile

Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).